Robert K Hamatake

US Patent:

8598334, Dec 3, 2013

Filed:

Oct 15, 2010

Appl. No.:

13/502370

Inventors:

Robert K. Hamatake - Durham NC, US

Assignee:

Glaxo Group Limited - Brentford, Middlesex

International Classification:

C07H 21/04
C12N 15/113

US Classification:

536 245, 514 44 A

Abstract:

Antisense oligomers useful for modulating hepatitis B virus infections, and for the treatment of hepatitis B virus (HBV) and hepatitis B virus-related conditions in animals including humans. More particularly, antisense oligomers with modified nucleotides for treatment of HBV in animals, more particularly antisense oligomers comprising 2′O-4′C-methylene-bridged sugars, or nucleotides with other 2′O-4′C bridged sugars, also known as locked nucleic acids (LNA), for treatment of HBV in animals, and more particularly for treatment of HBV in humans.

US Patent:

20060135556, Jun 22, 2006

Filed:

Aug 22, 2003

Appl. No.:

10/526249

Inventors:

Jean-Luc Girardet - Aliso Viejo CA, US
Zhijun Zhang - Harbor City CA, US
Robert Hamatake - Aliso Viejo CA, US
Martha de la Rosa - Fountain Valley CA, US
Esmir Gunic - Irvine CA, US
Zhi Hong - Aliso Viejo CA, US
Hong Kim - Irvine CA, US
Shahul Nilar - Irvine CA, US
Stephanie Shaw - Alhambra CA, US
Nanhua Yao - Irvine CA, US

International Classification:

A61K 31/4709
A61K 31/4196
A61K 31/4166

US Classification:

514307000, 514383000, 514398000, 514314000

Abstract:

Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.

US Patent:

58591877, Jan 12, 1999

Filed:

Jan 29, 1992

Appl. No.:

7/828789

Inventors:

James T. Matthews - Bedminster NJ
Katerina Leftheris - Skillman NJ
Robert K. Hamatake - Lawrenceville NJ
John T. Stevens - Levittown PA
Mary L. Haffey - Lawrenceville NJ

Assignee:

E. R. Squibb & Sons, Inc. - Princeton NJ

International Classification:

A61K 3800
A61K 3804
A61K 39245
A61K 3925

US Classification:

530326

Abstract:

Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulas W'--A. sub. 1 --A. sub. 2 --A. sub. 3 --A. sub. 4 --A. sub. 5 --A. sub. 6 --A. sub. 7 --A. sub. 8 --A. sub. 9 --A. sub. 10 --A. sub. 11 --X �SEQ. ID NO: 1! and Y'--A. sub. 12 --A. sub. 13 --A. sub. 14 --A. sub. 15 --A. sub. 16 --A. sub. 17 --Z �SEQ. ID NO: 2! that are useful as antiviral agents.

US Patent:

20140249143, Sep 4, 2014

Filed:

Oct 19, 2012

Appl. No.:

14/353067

Inventors:

- Philadelphia PA, US
Janos Botyanszki - Research Triangle Park NC, US
Eric Gregory Burroughs - Research Triangle Park NC, US
John George Catalano - Research Triangle Park NC, US
Wendy Huang Chern - Research Triangle Park NC, US
Hamilton D. Dickson - Research Triangle Park NC, US
Margaret J. Gartland - Research Triangle Park NC, US
Robert Hamatake - Research Triangle Park NC, US
Hans Hofland - Research Triangle Park NC, US
Jesse Daniel Keicher - Research Triangle Park NC, US
Christopher Brooks Moore - Research Triangle Park NC, US
John Bradford Shotwell - Research Triangle Park NC, US
Matthew David Tallant - Research Triangle Park NC, US
Jean-Philippe Therrien - Research Triangle Park NC, US
Shihyun You - Research Triangle Park NC, US

Assignee:

GlaxoSmithKline LLC - Philadelphia PA

International Classification:

C07D 471/14
C07D 498/14
C07D 491/048
C07D 513/04
C07D 471/04
C07D 498/04

US Classification:

5142302, 546 82, 544251, 514293, 514267, 546 81, 514292, 546 83, 514291, 544346, 514250, 544126, 5142332, 544101

Abstract:

Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.